Lv2
150 积分 2022-05-07 加入
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
1个月前
已完结
Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis
2个月前
已完结
Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy
2个月前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
3个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
3个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3个月前
已完结
Meta‐Analysis of Exposure‐Adverse Event Relationships for Antibody–Drug Conjugates
4个月前
已完结
皖公网安备34019202002308
